Sanofi

Traded on the St. Petersburg Stock Exchange
Sanofi is a French pharmaceutical company, formerly known as Sanofi-Aventis. It is one of the world's leading pharmaceutical corporations. It operates in more than one hundred countries. The company's headquarters is located in Paris. One of the most famous Sanofi products in Russia is Essentiale, Amaril, No-Spa, Festal, Lasolvan.
Sanofi stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Sanofi balance sheet

Report period2018 2019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, €
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Sanofi cash flows

Report period2018 2019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Sanofi multipliers

Report period2018 2019 2020 2021 2022 Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Sanofi profitability

Report period2018 2019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Sanofi assets
Sanofi cash flows
Sanofi dividends
3.62%

Sanofi dividend policy

The company pays dividends once a year

Sanofi shares

TickerNameTypeNominal valueISINPrice
SNY:USSanofiDepositary receipt-US80105N1054$48.07
Sanofi news
27.10.2023
Sanofi's IFRS net profit for 9 months of 2023 amounted to €5.994 billion, up 12.8% from €5.316 billion in the previous year. Revenue declined 0.4% to €32.151 billion from €32.272 billion a year earlier.
Source: {source} pictogram sanofi.com
Pictogram next
28.07.2023
Sanofi's IFRS net profit for 6 months of 2023 amounted to €3.456 billion, up 6.8% from €3.237 billion in the previous year. Revenue rose 2% to €20.187 billion from €19.79 billion a year earlier.
Source: {source} pictogram ml-eu.globenewswire.com
Pictogram next
27.04.2023
Sanofi's IFRS net profit for 3 months of 2023 was €2.009 billion, down 0.4% from €2.017 billion in the previous year. Revenue increased by 5.7% to €10.222 billion compared to €9.674 billion a year earlier.
Source: {source} pictogram ml-eu.globenewswire.com
Pictogram next
13.03.2023
Sanofi is buying U.S. pharmaceutical company Provention Bio for $2.9 billion, or $25 per share. Company is the developer of TZIELD, the only drug approved in the U.S. to slow the onset of Stage 3 Type 1 diabetes. Closing of deal is scheduled for the second quarter of 2023.
Source: {source} pictogram sanofi.com
Pictogram next
All Sanofi news
General information
Company nameSanofi
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address54 RUE LA BOETIE PARIS I0 75008 33153774400
Mailing address54 RUE LA BOETIE PARIS I0 75008
Websitewww.sanofi.com
Information disclosurewww.sec.gov